Abstract

The efficacy and safety of the vitamin D analog, doxercalciferol (1a-hydroxyvitamin D2, 1aD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report thse effect of 16-week 1aD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1aD2 treatment (–92%, –63% and –53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl.

Author Details

Authors

• M.S. Parisi
• B. Oliveri
• J. Somoza
• C. Mautalen

Departments

• Sección Osteopatías Médicas, Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina

Address

Log in for Subscribers

Citation